Jeito Capital logo

Jeito Capital

Europe, Ile-de-France, France, Paris

Description

Jeito Capital is a global investment company that invests in companies in the field of medical innovation.

Investor Profile

Jeito Capital has made 27 investments, with 7 in the past 12 months and 67% as lead.

Stage Focus

  • Series A (37%)
  • Series B (33%)
  • Series C (19%)
  • Series D (7%)
  • Series Unknown (4%)

Country Focus

  • United States (26%)
  • Switzerland (22%)
  • France (15%)
  • United Kingdom (11%)
  • Belgium (7%)
  • Germany (7%)
  • Denmark (7%)
  • The Netherlands (4%)

Industry Focus

  • Biotechnology
  • Medical
  • Therapeutics
  • Health Care
  • Pharmaceutical
  • Life Science
  • Health Diagnostics
  • Medical Device
  • Product Research
  • Biopharma
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Jeito Capital frequently co-invest with?

OrbiMed
North America, New York, United States, New York
Co-Investments: 3
Omega Funds
Europe, Geneve, Switzerland, Geneva
Co-Investments: 5
SV Health Investors
North America, Massachusetts, United States, Boston
Co-Investments: 5
UPMC Enterprises
North America, Pennsylvania, United States, Pittsburgh
Co-Investments: 4
Forbion Capital Partners
Europe, Noord-Holland, The Netherlands, Naarden
Co-Investments: 5
Novo Holdings
Europe, Hovedstaden, Denmark, Hellerup
Co-Investments: 7
Pureos Bioventures
Europe, Zurich, Switzerland, Küsnacht
Co-Investments: 4
V-Bio Ventures
Europe, Oost-Vlaanderen, Belgium, Gent
Co-Investments: 3
Bpifrance
Europe, Ile-de-France, France, Maisons-alfort
Co-Investments: 5
Inkef
Europe, Noord-Holland, The Netherlands, Amsterdam
Co-Investments: 3

What are some of recent deals done by Jeito Capital?

Augustine Therapeutics

Leuven, Vlaams-Brabant, Belgium

Augustine Therapeutics is discovering and developing innovative medicines for the treatment of neuromuscular and neurodegeneratives diseases

BiopharmaBiotechnologyPharmaceutical
Series AMar 24, 2025
Amount Raised: $84,139,626
Callio Therapeutics

Seattle, Washington, United States

Callio Therapeutics develops next-generation, multi-payload antibody-drug conjugates (ADCs).

BiotechnologyHealth CareMedical
Series AMar 3, 2025
Amount Raised: $187,000,000
XyloCor Therapeutics

King Of Prussia, Pennsylvania, United States

XyloCor Therapeutics is a biopharmaceutical company intended to develop gene therapy for people with coronary artery disease.

BiotechnologyHealth CarePharmaceutical
Series BJan 7, 2025
Amount Raised: $67,500,000
Aviceda Therapeutics

Cambridge, Massachusetts, United States

Aviceda Therapeutics is a late-stage pre-clinical biotech company developing drugs for treating glyco-immune diseases.

BiotechnologyHealth CareLife SciencePharmaceuticalTherapeutics
Series CJan 7, 2025
Amount Raised: $207,500,000
Noema Pharma

Basel, Basel-Stadt, Switzerland

Noema Pharma is a biotech company that develops therapies to address disabling symptoms in conditions of the brain and nervous system.

BiotechnologyMedicalPharmaceutical
Series BDec 11, 2024
Amount Raised: $30,567,953
Alentis Therapeutics

Allschwil, Basel-Landschaft, Switzerland

ALENTIS Therapeutics is a Swiss-French biotech company developing novel therapeutics in advanced liver disease and cancer.

BiotechnologyManufacturingPharmaceuticalTherapeutics
Series DNov 12, 2024
Amount Raised: $181,400,000
CatalYm

Planegg, Bayern, Germany

CatalYm is a biotechnology company developing innovative immunotherapies for cancer patients.

BiotechnologyHealth CareMedicalTherapeutics
Series DJul 16, 2024
Amount Raised: $150,000,000
HI-Bio

South San Francisco, California, United States

Human Immunology Biosciences is a biotechnology company that focuses on developing therapies for immune-mediated diseases.

BiotechnologyLife ScienceMedicalProduct ResearchTherapeutics
Series BJan 4, 2024
Amount Raised: $95,000,000
NMD Pharma

Risskov, Midtjylland, Denmark

NMD Pharma is a small molecule drug discovery company that develops novel treatments of neuromuscular disorders.

MedicalPharmaceuticalTherapeutics
Series BNov 15, 2023
Amount Raised: $81,409,005
Eyebiotech

New York, New York, United States

Eyebiotech is an ophthalmology biotechnology company that specializes in therapies for eye diseases.

BiotechnologyMedical
Series ANov 14, 2023
Amount Raised: $65,000,000